65,437 trials
Total Knee Arthroplasty · Knee Pain
Primary: Quadriceps Femoris Muscle Strength Maximum Voluntary Isometric Contraction (MVIC) — 13; 12 newtons — p=0.05
Urothelial Carcinoma
Primary: Median Overall Survival — 13.9 months
Lower Back Pain
Primary: Intervention Erector Spinae Stiffness Change — -10.959 Newton metres (Nm) — p=<0.05
Psoriasis Vulgaris
Primary: Change From Screening in Serum Albumin Levels at Week 4 — -1.0 gram per liter (g/L)
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Human Immunodeficiency Virus
Primary: Change in Antiretroviral Therapy (ART) Adherence Rates — 27.04; 26.25; 26.14; 26.48 score on a scale
Cocaine Dependence
Primary: Weeks of Abstinence From Cocaine — 1.0; 1.0 weeks
Systemic Lupus Erythematosus
Primary: Number of Deaths - On Treatment Period (Week 52) — 8; 10 Participants
Cardiac Surgery
Primary: Number of Participants With NIV Failure — 10; 8 Participants — p=0.831
Rosacea
Primary: Percent Change From Baseline in Inflammatory Lesion Count at Week 12 — -80.29; -73.56 percent change — p=0.032
Anaemia
Primary: Mean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) — 10.89; 10.83 Grams per deciliter (g/dL) — p=<.0001
Asthma
Primary: Equivalence Analysis of Area Under the Serial FEV1-Time Effect Curve From Time 0 to 12 Hours (FEV1 Area Under Curve [AUC0-12]) on the First Day of Treatment — 3.637…
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Respiratory Symptoms Measured by Evaluating Respiratory Symptoms (E-RS) in COPD. E-RS: COPD Total Score — -2.11; -1.93; -1.47; -0.87 Scores on a…
Congestive Heart Failure
Primary: Percentage of Subjects Who Are Free of Complications Related to the Corox LV Lead — 94.19 percentage of subjects — p=<0.0001
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants